UBS Group’s Cellectar Biosciences, Inc. CLRBW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-350
| Closed | – | – | 8547 |
|
|
2019
Q2 | $0 | Hold |
350
| – | – | ﹤0.01% | 8420 |
|
|
2019
Q1 | $0 | Sell |
350
-20
| -5% | -$2 | ﹤0.01% | 8492 |
|
|
2018
Q4 | $0 | Sell |
370
-100
| -21% | -$9 | ﹤0.01% | 8530 |
|
|
2018
Q3 | $0 | Hold |
470
| – | – | ﹤0.01% | 8481 |
|
|
2018
Q2 | $0 | Sell |
470
-100
| -18% | -$25 | ﹤0.01% | 8449 |
|
|
2018
Q1 | $0 | Hold |
570
| – | – | ﹤0.01% | 8401 |
|
|
2017
Q4 | $0 | Hold |
570
| – | – | ﹤0.01% | 8277 |
|
|
2017
Q3 | $0 | Hold |
570
| – | – | ﹤0.01% | 8181 |
|
|
2017
Q2 | $0 | Buy |
570
+20
| +4% | +$5 | ﹤0.01% | 8204 |
|
|
2017
Q1 | $0 | Buy |
550
+510
| +1,275% | +$146 | ﹤0.01% | 8201 |
|
|
2016
Q4 | $0 | Buy |
+40
| New | +$9 | ﹤0.01% | 8218 |
|
|
2016
Q3 | – | Sell |
-259
| Closed | – | – | 8113 |
|
|
2016
Q2 | $0 | Buy |
+259
| New | +$158 | ﹤0.01% | 8126 |
|
UBS Group's CLRBW Position: Q3 2019 in Review
UBS Group sold out of Cellectar Biosciences, Inc. (CLRBW) in Q3 2019, closing a stake of 350 shares.
UBS Group first reported a position in CLRBW in Q2 2016 and held it in 12 quarters. The position peaked at $0 in Q2 2019. 0 funds tracked by Wall St. Rank hold CLRBW as of Q3 2019.
- UBS Group reported no remaining Cellectar Biosciences, Inc. position as of Q3 2019 after selling out during the quarter.
- UBS Group sold 350 Cellectar Biosciences, Inc. shares in Q3 2019.
- UBS Group first reported a position in Cellectar Biosciences, Inc. in Q2 2016 and held it in 12 quarters.
- UBS Group's Cellectar Biosciences, Inc. position peaked at $0 in Q2 2019.
- 0 funds tracked by Wall St. Rank held Cellectar Biosciences, Inc. as of Q3 2019.
Based on UBS Group's 13F filing for Q3 2019, filed 14 Nov 2019.